Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic t cells by a cd40-targeted adenovirus

Journal of Immunotherapy

Volumn 33, Issue 7, 2010, Pages 706-715

  Hangalapura, Basav N ^a   Oosterhoff, Dinja ^a   Aggarwal, Shikhar ^a   Wijnands, Pepijn G J T B ^a   Van De Ven, Rieneke ^a   Santegoets, Saskia J A M ^a   Van Den Tol, Monique Petrousjka ^a   Hooijberg, Erik ^a   Pereboev, Alexander ^b   Van Den Eertwegh, Alfons J M ^a   Curiel, David T ^b   Scheper, Rik J ^a   De Gruijl, Tanja D ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b University of Alabama at Birmingham   (United States)

Author keywords

adenovirus; CD40; CTL; DC; melanoma

Indexed keywords

ADENOVIRUS VECTOR; CD40 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; HYBRID PROTEIN; MELAN A; MELANOMA ANTIGEN; TUMOR NECROSIS FACTOR;

ARTICLE; BINDING AFFINITY; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPH NODE; MELANOMA; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADENOVIRIDAE; ANTIGENS, CD4; ANTIGENS, CD40; CD40 LIGAND; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; K562 CELLS; LYMPH NODES; MART-1 ANTIGEN; MELANOMA; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY; TRANSDUCTION, GENETIC;

EID: 77955176713     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181eccbd4     Document Type: Article

References (52)

1. Steinman RM, Nussenzweig MC. Avoiding horror autotox-icus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA. 2002;99:351-358.
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
3. Palucka AK, Dhodapkar MV, Paczesny S, et al. Boosting vaccinations with peptide-pulsed CD34+ progenitor-derived dendritic cells can expand long-lived melanoma peptide-specific CD8+ T cells in patients with metastatic melanoma. J Immunother. 2005;28:158-168.
4. Redman BG, Chang AE, Whitfield J, et al. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J Immunother. 2008;31:591-598.
5. Adema GJ, de Vries IJ, Punt CJ, et al. Migration of dendritic cell based cancer vaccines: in vivo veritas? Curr Opin Immunol. 2005;17:170-174.
6. Korokhov N, Noureddini SC, Curiel DT, et al. A single-component CD40-targeted adenovirus vector displays highly efficient transduction and activation of dendritic cells in a human skin substrate system. Mol Pharm. 2005;2:218-223.
7. Timares L, Douglas JT, Tillman BW, et al. Adenovirus-mediated gene delivery to dendritic cells. Methods Mol Biol. 2004;246:139-154.
8. de Gruijl TD, Pinedo HM, Scheper RJ. Immunotherapy of cancer by dendritic cell-targeted gene transfer. In: Curiel DT, Douglas JT, eds. Immunotherapy of Cancer by Dendritic
9. Cell-targeted Gene Transfer. Totowa NJ: Humana Press Inc; 2005:143-184. 9. Smith JS, Tian J, Lozier JN, et al. Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. Mol Ther. 2004;9:932-941.
10. Shortman K, Lahoud MH, Caminschi I. Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med. 2009;41:61-66.
11. Henning P, Andersson KM, Frykholm K, et al. Tumor cell targeted gene delivery by adenovirus 5 vectors carrying knobless fibers with antibody-binding domains. Gene Ther. 2005;12:211-224.
12. Henning P, Magnusson MK, Gunneriusson E, et al. Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum Gene Ther. 2002;13:1427-1439.
13. Noureddini SC, Krendelshchikov A, Simonenko V, et al. Generation and selection of targeted adenoviruses embodying optimized vector properties. Virus Res. 2006;116:185-195.
14. Parrott MB, Adams KE, Mercier GT, et al. Metabolically biotinylated adenovirus for cell targeting, ligand screening, and vector purification. Mol Ther. 2003;8:688-700.
15. Brandao JG, Scheper RJ, Lougheed SM, et al. CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine. 2003;21:2268-2272.
16. Li Y, Yao XM, Hong-Brown L, et al. Adaptable modification of adenoviral tropism using a bifunctional ligand protein. Virus Res. 2003;91:223-230.
17. Pereboev AV, Asiedu CK, Kawakami Y, et al. Coxsackievirus-adenovirus receptor genetically fused to anti-human CD40 scFv enhances adenoviral transduction of dendritic cells. Gene Ther. 2002;9:1189-1193.
18. Sapinoro R, Maguire CA, Burgess A, et al. Enhanced transduction of dendritic cells by FcgammaRI-targeted ade-novirus vectors. J Gene Med. 2007;9:1033-1045.
19. Korokhov N, de Gruijl TD, Aldrich WA, et al. High efficiency transduction of dendritic cells by adenoviral vectors targeted to DC-SIGN. Cancer Biol Ther. 2005;4:289-294.
20. De Gruijl TD, Luykx-de Bakker SA, Tillman BW, et al. Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol. 2002;169: 5322-5331.
21. Huang D, Pereboev AV, Korokhov N, et al. Significant alterations of biodistribution and immune responses in Balb/c mice administered with adenovirus targeted to CD40(+) cells. Gene Ther. 2008;15:298-308.
22. Tillman BW, de Gruijl TD, Luykx-de Bakker SA, et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol. 1999;162:6378-6383.
23. Diehl L, den Boer AT, Schoenberger SP, et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med. 1999;5:774-779.
24. Hawiger D, Inaba K, Dorsett Y, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med. 2001;194:769-779.
25. MacLeod M, Kwakkenbos MJ, Crawford A, et al. CD4 memory T cells survive and proliferate but fail to differentiate in the absence of CD40. J Exp Med. 2006;203:897-906.
26. Schumacher L, Ribas A, Dissette VB, et al. Human dendritic cell maturation by adenovirus transduction enhances tumor antigen-specific T-cell responses. J Immunother. 2004;27: 191-200.
27. Tillman BW, Hayes TL, DeGruijl TD, et al. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res. 2000;60:5456-5463.
28. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity. 2008;29:319-324.
29. Molenkamp BG, van Leeuwen PA, Meijer S, et al. Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res. 2007;13:2961-2969.
30. Chakraborty NG, Chattopadhyay S, Mehrotra S, et al. Regulatory T-cell response and tumor vaccine-induced cyto-toxic T lymphocytes in human melanoma. Hum Immunol. 2004;65:794-802.
31. Palucka AK, Dhodapkar MV, Paczesny S, et al. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother. 2003;26:432-439.
32. Banchereau J, Ueno H, Dhodapkar M, et al. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother. 2005;28:505-516.
33. Bontkes HJ, De Gruijl TD, Schuurhuis GJ, et al. Expansion of dendritic cell precursors from human CD34(+) progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. J Leukoc Biol. 2002;72:321-329.
34. Schreurs MW, Scholten KB, Kueter EW, et al. In vitro generation and life span extension of human papillomavirus type 16-specific, healthy donor-derived CTL clones. J Immunol. 2003;171:2912-2921.
35. Yssel H, De Vries JE, Koken M, et al. Serum-free medium for generation and propagation of functional human cytotoxic and helper T cell clones. J Immunol Methods. 1984;72:219-227.
36. Bakker AB, Schreurs MW, de Boer AJ, et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med. 1994; 179:1005-1009.
37. Plog MS, Guyre CA, Roberts BL, et al. Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. Hum Gene Ther. 2006;17:705-716.
38. Labow D, Lee S, Ginsberg RJ, et al. Adenovirus vector-mediated gene transfer to regional lymph nodes. Hum Gene Ther. 2000;11:759-769.
39. Pereboev AV, Nagle JM, Shakhmatov MA, et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther. 2004;9: 712-720.
40. Karpusas M, Hsu YM, Wang JH, et al. 2 A crystal structure of an extracellular fragment of human CD40 ligand. Structure. 1995;3:1031-1039.
41. Banchereau J, Paczesny S, Blanco P, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci. 2003;987:180-187.
42. Cella M, Facchetti F, Lanzavecchia A, et al. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol. 2000;1:305-310.
43. Salio M, Cella M, Vermi W, et al. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol. 2003;33:1052-1062.
44. Speiser DE, Lienard D, Rufer N, et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest. 2005; 115:739-746.
45. Lore K, Adams WC, Havenga MJ, et al. Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol. 2007;179:1721-1729.
46. Meier O, Boucke K, Hammer SV, et al. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J Cell Biol. 2002;158:1119-1131.
47. Cochran AJ, Huang RR, Lee J, et al. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol. 2006;6:659-670.
48. Butterfield LH, Jilani SM, Chakraborty NG, et al. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 1998; 161:5607-5613.
49. Tuettenberg A, Jonuleit H, Tuting T, et al. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. Gene Ther. 2003;10:243-250.
50. Butterfield LH, Comin-Anduix B, Vujanovic L, et al. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008;31: 294-309.
51. Granelli-Piperno A, Pritsker A, Pack M, et al. Dendritic cell-specific intercellular adhesion molecule 3-grabbing noninte-grin/CD209 is abundant on macrophages in the normal human lymph node and is not required for dendritic cell stimulation of the mixed leukocyte reaction. J Immunol. 2005;175:4265-4273.
52. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 1998;90:1894-1900.